Format
Sort by

Send to

Choose Destination

Search results

Items: 3

1.

Composite end points to assess delay of disability progression by MS treatments.

Zhang J, Waubant E, Cutter G, Wolinsky J, Leppert D.

Mult Scler. 2014 Oct;20(11):1494-501. doi: 10.1177/1352458514527180. Epub 2014 Mar 27.

PMID:
24675040
2.

EDSS variability before randomization may limit treatment discovery in primary progressive MS.

Zhang J, Waubant E, Cutter G, Wolinsky JS, Glanzman R.

Mult Scler. 2013 May;19(6):775-81. doi: 10.1177/1352458512459685. Epub 2012 Oct 1.

PMID:
23027880
3.

Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial.

Hawker K, O'Connor P, Freedman MS, Calabresi PA, Antel J, Simon J, Hauser S, Waubant E, Vollmer T, Panitch H, Zhang J, Chin P, Smith CH; OLYMPUS trial group.

Ann Neurol. 2009 Oct;66(4):460-71. doi: 10.1002/ana.21867.

PMID:
19847908

Supplemental Content

Loading ...
Support Center